The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
Active (recruiting)
Recruitment start date:
27/09/2012
Funder:
Cancer Research UK
Sponsor:
UCL
Chief Investigator:
Mary McCormack
Recruitment target:
500
EudraCT number:
2011-001300-35
Contact details:
ctc.interlace@ucl.ac.uk
Lay summary:
INTERLACE
A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation vs standard chemoradioation alone in patients with locally advanced cervical cancer
Description
Design: INTERLACE is a phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer.
Treatment: Patients will be randomised to receive either the current standard treatment of chemoradiation (cisplatin chemotherapy followed by radiotherapy) for 5 weeks, or they will be randomised to receive 6 weeks of induction chemotherapy, comprised of carboplatin and paclitaxel followed by the standard chemoradiation. 
Key inclusion/exclusion criteria: Patients must have histologically confirmed FIGO stage IB2 – IVa squamous, adeno or adenosquamous carcinoma of the cervix (except those with disease extending to the lower third of the vagina). Patients with FIGO stage IB1 and positive lymph nodes are also eligible. They must be deemed fit to receive radical chemoradiation and carboplatin and paclitaxel and have an adequate renal, liver and bone marrow function. Patients will be not be eligible if they have had a previous pelvic malignancy regardless of the interval since diagnosis or a previous malignancy not affecting the pelvis (except basal cell carcinoma of the skin) where disease free interval is less than 10 years. Evidence of distant metastases would also make a patient ineligible.
Duration of recruitment: Recruitment is ongoing. 
Aim
The overall aim of the INTERLACE trial is to investigate whether an additional short-course of chemotherapy given on a weekly schedule immediately before standard chemoradiation leads to an improvement in overall survival in women with locally advanced cervical cancer. 

The CRUK & UCL Cancer Trials Centre has produced three videos aimed at patients considering entering INTERLACE, a trial investigating the treatment of cervical cancer. The videos feature two INTERLACE patients who underwent treatment at University College Hospital (UCLH), as well as interviews with trial chief investigator Dr Mary McCormack (pictured) and UCLH cancer nurses Karen Summerville and Egla Aitkens. 

You can watch them using the links below:

Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us